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Mature, active cysteine cathepsins (CPs) were identified in human inflammatory bronchoalveolar lavage fluid (BALF) supernatants from
patients suffering from silicosis by both western blot and surface plasmon resonance analyses. BALFs are not a reservoir of activatable proforms,
since no autocatalytic maturation at acidic pH occurs. Cathepsin H is the most profuse among studied CPs (median value: 36.5 nM), while
cathepsins B and L are the two most abundant thiol-dependent endoproteases. The overall concentration of active cathepsins B, H, K, L, and S is
¨10-fold lower than their concentration in BALF supernatants from patients suffering from inflammatory acute lung injuries (962T347 nM).The
cathepsins (approximately 70 nM)/cystatin-like inhibitors (approximately 9 nM) ratio is unbalanced in favor of enzymes (¨8-fold). This presence
of uncontrolled CPs suggests that they may contribute, in addition to matrix metalloproteases, to the lung tissue breakdown/remodeling occurring
during silicosis, although their exact contribution to interstitial inflammation remains to be evaluated.
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Silicosis is an occupational lung disease that is characterized
by chest X-rays showing rounded opacities. Patients suffer from
fatigue, dry cough, weight loss, decreased pulmonary function,
compromised gas exchange, and often develop cyanosis (as
reviewed in [1]). Pulmonary hypertension and chronic hypox-
emia may cause death in severe forms of the disease. Even
though this pneumoconiosis may be prevented by environmen-
tal dust control, it occurs still frequently and peculiarly among
workers in developing countries. Silicosis is caused by
inhalation of crystalline silica, particularly in high-hazard
occupations (e.g., mining, sandblasting, tunneling, or rock0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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Abbreviations: AMC, 7-amino-4-methyl coumarin; BALF, bronchoalveolar
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addition to a possible link with lung carcinoma, silicosis is also
associated with systemic and autoimmune diseases such as
scleroderma and rheumatoid arthritis [3]. Despite the patho-
physiological mechanisms remain unclear, it is established that
the lung responds to silica by triggering an inflammatory
cascade of reactions. Alveolar macrophages release reactive
nitrogen and oxygen species, and inflammatory cytokines [4].
Upregulation of antioxidant enzymes, induction of inflamma-
tory factors (IL-1, IL-6, TNF-alpha, and TGF-beta), activation
of NF-nB, and of lipid peroxidation are observed [5].
Furthermore silicotic lungs showed increased collagenase and
gelatinase activity. Silica deposition also resulted in apoptosis
associated with inflammatory infiltrates in lung parenchyma [6].
Most studies on the lung proteolytic enzymes involved in
degradation of collagen have focused primarily on MMPs (see,
for review, [7]). Early granulomas exhibit intense staining for
matrix metalloproteinases in experimental silicosis [8], and
MMP-2, MMP-9, and stromelysin activities increase progres-
sively in alveolar macrophages during fibrotic responses [9].
Conversely, their inhibitors (TIMP-1 and TIMP-2) showed a
moderate reduction in late silicotic nodules, suggesting that an1762 (2006) 351 – 356
http://www
Table 1
Bronchoalveolar lavages: cell counts (expressed as %)
Patient no. Macrophages (%) Lymphocytes (%) Neutrophils (%
1 93 5 2
2 98 2 <1
3 100 0 0
4 95 5 0
5 94 5 1
6 93 5 2
7 91 7 2
8 93 7 <1
9 91 7 2
10 98 2 <1
11 98 1 1
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implicated in ECM remodeling and basement membrane
disruption. At the noticeable exception of caspases (family
C14) which are core effectors of apoptosis (as reviewed by
Denault and Salvesen [10]), no study has been reported so far
about the presence and the putative role of cysteine proteases.
Papain-related cysteine cathepsins (family C1) participate to a
variety of proteolytic processes (e.g., turnover of endocytosed
proteins, prohormone processing, MHC-II antigen presentation)
[11]. Cathepsins are also involved in diseases such as tumor
metastasis, osteoporosis, or rheumatoid arthritis, and are drug
targets of clinical interest [12,13]. While cathepsin H is
preferentially found in type II pneumocytes, lung CPs are
mainly expressed by macrophages, fibroblasts and epithelial
cells [14,15]. Stimulated monocyte-derived macrophages can
release CPs [16], that are found in bronchoalveolar lavage fluids
(BALFs) of smokers [17]. Recently we identified also active
forms of cysteine cathepsins B, H, K, L and S in cell-free
supernatants of BAL fluids from patients suffering of infiltrative
inflammatory disorders (e.g., sarcoidosis, alveolar proteinosis)
[18]. Even though CP activity is regulated by their natural
inhibitors (CPIs), including both cystatin C and kininogens, the
CP/CPI ratio was significantly unbalanced in favor of proteol-
ysis (3/5-fold), as confirmed by the CP-dependent degradation
of exogenous kininogens by BALFs [18]. That supports that, in
addition to neutrophile elastase and MMPs, elastolytic CPs are
involved in the degradation and/or remodeling of ECM [19–
21]. The aim of this work was to characterize the presence of
enzymatically active forms of cysteine cathepsins in BALFs of
patients suffering from silicosis, and evaluated the imbalance
between CPs and their specific inhibitors. This was done by
assaying mature cathepsins B, H, K, L and S, their proforms and
their endogenous inhibitors (kininogens and cystatin C).
2. Materials and methods
2.1. Patient selection and biological samples
Eleven elligible patients (Department of Pneumology, Bretonneau Uni-
versity Hospital, Tours, France) that fulfilled the diagnostic criteria for
silicosis as set out in the consensus American-European guidelines (i.e., with a
history of exposure to silica and chest X-ray interpretation showing rounded
opacities) were included in the study. Time inclusion was from 12-01-2002 to
12-01-2004. All were negative for emphysema and tuberculosis. Three of
these subjects were smokers, but abstained from cigarette smoking for 72
h before bronchoscopy. They were negative for viral serologies (HVB, HIV,
CMV). None of them were under long or short course treatment with heparin,
corticosteroids, and non-steroidal anti-inflammatory agents. Bronchoalveolar
lavages were performed according to recommendations and guidelines of the
European Respiratory Society. Due to the French policies and ethical
considerations, lavages were not applied to healthy (control) subjects. Briefly
aliquots of sterile saline were infused at room temperature to the lingula or the
middle lobe, and immediately gently reaspirated. The first aliquot was
collected separately, and not used for further biochemical studies. Cytological
data are reported in Table 1. BAL fluid samples were immediately filtered and
buffered (final concentration: 0.1 M Na-acetate, pH 5.0, plus the peptidase
inhibitors 0.4 mM PMSF, 0.1 mM EDTA, 0.04 mM pepstatin A, and 1 mM
MMTS). After centrifugation (2000g; 4 -C) for 15 min as reported
elsewhere [18], the resulting cell-free supernatants were aliquoted, their
protein content quantified using the Bradford reagent (BioRad, Hercules,
USA), and frozen at 80 -C.)2.2. Enzymes and inhibitors
N-(4-Biphenylacetyl)-S-methylcysteine-(d)-Arg-Phe-h-phenethylamide
and human high molecular weight kininogen were from Calbiochem (VWR
International, Libourne, France). CA-074, E-64, PMSF, pepstatin A, EDTA and
MMTS were from Sigma-Aldrich (Saint-Quentin Fallavier, France). DTT (DL-
dithiotreitol) came from Bachem (Weil am Rhein, Germany). Human
cathepsins B, L, and H, and bovine cathepsin S were supplied by Calbiochem.
Recombinant human cathepsin K, expressed in Pichia pastoris, was a kind gift
from Dieter Bro¨mme (University of British Columbia, Vancouver, Canada). H-
Arg-AMC, Z-Arg-Arg-AMC and Z-Phe-Arg-AMC were purchased from
Bachem and Z-Leu-Arg-AMC from ICN Biochemical (Aurora, USA). All
other reagents were of analytical grade.
2.3. Immunoblotting
The specific primary antibodies were: rabbit anti-human cathepsin B
(Fitzgerald, Concord, USA), rabbit anti-human cathepsin H (Fitzgerald), rabbit
anti-human cathepsin L (Fitzgerald), mouse anti-human cathepsin S (Krka,
Ljubljana, Slovenia), rabbit anti-human cystatin C (Upstate, Lake Placid,
USA), and rabbit anti-human high and low molecular weight kininogens [22];
the rabbit anti-human cathepsin K antibody was a kind gift from Dieter
Bro¨mme (University of British Columbia, Vancouver, Canada). The goat anti-
rabbit IgG-peroxidase conjugate and the goat anti-mouse IgG-peroxidase
conjugate were both from Sigma-Aldrich. Prestained molecular masses were
from Cell Signaling (Saint Quentin en Yvelines, France). BAL fluids (7
Al)were diluted and boiled in reducing sample buffer (14 Al) prior separation
by SDS-PAGE on 12% gels (1 h30, 20 mA) and electro transfer to a
nitrocellulose sheet (1 h, 30 mA). After saturation in PBS, 0.1% Tween 20,
10% skim dry milk for 1 h at room temperature, the membrane was incubated
with the primary antibody (1:1000, in PBS, 0.1% Tween, 3% skim dry milk)
for 1 h at room temperature, then with a goat anti-rabbit IgG-peroxidase
conjugate (1:5000) for 1 h at room temperature (or with a goat anti-mouse
IgG-peroxidase conjugate (1:1000) for detection of the mouse anti-human
cathepsin S). Revelation was done by using the Renaissance 4 CN plus (4-
chloro-1-naphthol) system (NEN Life Science, Zaventem, Belgium), or
alternatively by an ECL kit (Amersham Pharmacia Biotech, Buckinghamshire,
England).
2.4. In vitro labeling of cysteine cathepsins
Cathepsins B, H, K, L and S (1 AM) were incubated in the assay buffer with
a molar excess (1:300) of a cystatin-derived probe, i.e., Biot-LVG-CHN2
[23,24], for 1 h at 37 -C. Samples were further subjected to a 12% (w/v) SDS-
PAGE under reducing conditions. Proteins were blotted before the nitrocellu-
lose sheet was saturated by incubation for 1 h at 37 -C with PBS containing 1%
(w/v) BSA. After washing with PBS containing 0.1% Tween 20, and incubation
with an extravidin-peroxidase conjugate (diluted 1:500) for 2 h at room
temperature, the peroxidase activity was revealed in the presence of 4-chloro-1-
naphthol. Control experiments were performed by pre-incubating cathepsins
with E-64 (100 AM) prior adding the biotinylated probe.
Fig. 1. Immunodetection of cysteine cathepsins. Western blot analyses of
bronchoalveolar lavage fluids were performed using rabbit polyclonal
antibodies against human cathepsins B (lanes 1–3), L (lanes 4–6), H (lanes
7–9), and a mouse monoclonal antibody against human cathepsin S (lanes 10–
12). Three representative silicotic BALF samples are shown for the sake of
clarity: lanes 1, 4, 7, 10, BALF #1, lanes 2, 5, 8, 11, BALF #2, lanes 3, 6, 9, 12,
BALF #3.
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cathepsins from BAL fluids
BAL fluids were incubated in the assay buffer with Biot-LVG-CHN2 (100
AM), for 4 h at 30 -C. The excess of activity-based probe was carefully removed
by successive dialysis/concentration steps (Vivaspin, 4 000 rpm, 5 min, cut-off :
10,000) in order to avoid any further unwanted interactions between streptavidin-
coated dextran and free residual Biot-LVG-CHN2. A control experiment was
done by using an unlabelled inhibitor, i.e., E-64 (5 AM). Samples were finally
diluted in 0.1 M Na-phosphate, pH 6.0, 2 mM DTT, prior to analysis by surface
plasmon resonance (SPR) using a BIAcore 1000 system (Uppsala, Sweden).
Briefly, the streptavidin coated sensorchip SA5 (BIAcore International) was
washed three times by injecting 5 Al of 1 MNaCl and 50 mMNaOH as indicated
by the manufacturer. Immobilization of samples containing Biot-LVG-CHN2-
labeled cysteine cathepsins was performed as described previously with a few
modifications [25], by using 0.1MNa-phosphate, pH 6.0, 2 mMDTTas running
buffer at a continuous flow rate of 5 Al/min. The specificity of the interaction was
checked using BALF samples containing E-64-treated cysteine cathepsins. After
6min of washingwith running buffer, the strength (affinity) of the interactionwas
evaluated by injecting 5 Al NaOH 20 mM.
2.6. CP activity and CPI potential of bronchoalveolar lavage fluids
CPs from BALFs (20 Al/assay)were activated in their activity buffer (100
mM Na-phosphate buffer pH 6.0 containing 2 mM DTT and 2 mM EDTA) for
3 min at 30 -C, prior to making kinetic measurements in the presence of a panel
of AMC-derived fluorogenic substrates. Hydrolysis was continuously recorded
at 30 -C with a Kontron SFM 25 spectrofluorimeter (kexc=350 nm and
kem=460 nm). Thiol-dependent endoproteases (i.e., cathepsins B+K+L+S)
were active site-titrated with E-64 (0–10 nM final), using Z-Phe-Arg-AMC as
substrate (5 AM), according to Barrett and coworkers [26]. Pre-incubation with
a large excess (5 AM)of N-(4-Biphenylacetyl)-S-methylcysteine-(d)-Arg-Phe-
h-phenethylamide, a specific inhibitor of cathepsin L [27] allowed us to deduce
the average concentration of cathepsins B+K+S. Cathepsin B was titrated with
N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-l-isoleucyl-l-proline (CA-
074) (0–10 nM) using Z-Arg-Arg-AMC as substrate (5 AM) [28]. Increasing
concentrations of titrated cathepsin S (0–1 nM) were incubated for 1 h at 37 -C
in 100 mM Na-phosphate buffer pH 7.4, before addition of Z-Leu-Arg-AMC (5
AM) and monitoring of the residual enzymatic activity; concentration of BALF
cathepsin S was further deduced from this calibration curve according to its
unusual stability at mildly basic pH [29,30]. Concentration of cathepsin K was
estimated from the difference between the concentration of E-64-titrated
cathepsins B+K+S and the individual concentrations of both cathepsins B and
S. Concentration of cathepsin L was deduced from the difference between the
concentration of thiol-dependent endoproteases (i.e., cathepsins B+K+L+S)
and the respective concentrations of cathepsins B, K and S. The aminopeptidase
activity of cathepsin H was quantified by monitoring the enzymatic activity of
increasing concentrations of titrated cathepsin H (0–40 nM), in presence of H-
Arg-AMC (5 AM) at 30 -C in the assay buffer. Concentration of cathepsin H
issued from BAL samples was deduced from this calibration curve. The
experimental procedure to evaluate the BALF inhibitory potential was adapted
from a previous report by Assfalg-Machleidt et al. [31]. According to that thiol-
dependent endoproteases of BAL fluids are mostly represented by cathepsins B
and L (86%), their specific CP activity was blocked by pre-incubation for 30
min by both CA-074 (1 AM) and N-(4-Biphenylacetyl)-S-methylcysteine-(d)-
Arg-Phe-h-phenethylamide (1 AM). The BALF inhibitory potential was further
deduced by addition of increasing amounts of BALF (0–16 Al) by using E-64
titrated papain (3 nM), in presence of Z-Phe-Arg-AMC (5 AM) as substrate.
3. Results and discussion
3.1. Immunodetection and labeling of cysteine cathepsins from
BAL fluids
Cell-free supernatants of bronchoalveolar lavage fluids were
buffered at acidic pH (0.1 M acetate buffer pH 5.0) in presenceof a cocktail of protease inhibitors (1 mM PMSF, 1 mM EDTA,
0.04 mM pepstatin A, 1 mM MMTS) to stabilize and preserve
cysteine cathepsins from pH inactivation and uncontrolled
proteolysis. The median protein concentration, determined
using the Bradford procedure, was 0.08 mg/ml (min. value:
0.02 mg/ml; max. value: 0.16 mg/ml). Immunoreactive
cathepsins B, H, and L (approximately 25 kDa) (lines 1–9),
but not cathepsins S (lines 10–12) and K (not shown), were
detected in all BALF samples (Fig. 1). On the other hand, no
bands corresponding to proforms of the enzymes were stained,
indicating that cathepsins were fully processed into their
mature forms or that the zymogene concentrations were too
low to be detected under our experimental conditions. These
results differ significantly from a previous study performed on
BAL fluids from patients suffering from infiltrative inflamma-
tory disorders (e.g., sarcoidosis, alveolar proteinosis) [18], that
showed that cathepsins B, K and S are mainly detected as
zymogens, whereas cathepsins H and L were predominantly
mature forms. Alternatively, we have investigated the ability of
Biot-LVG-CHN2, a cystatin C-derived probe initially designed
to target parasite cysteine proteinases from Trypanosoma cruzi,
T. congolense, and Plasmodium falciparum [24–32], to bind to
active forms of BALF cathepsins. By contrast with rat
cathepsins B and L [23], this activity-based probe efficiently
labelled purified human cathepsins B, L, K and H, and bovine
cathepsin S (Fig. 2). Preincubation of cathepsins with E-64
abolished binding, confirming the specific targeting of the
active site-reactive thiol by Biot-LVG-CHN2. However after
incubation of BALF samples with Biot-LVG-CHN2, no
reactive bands could be revealed using an extravidin-peroxi-
dase conjugate (not shown). In order to outline this problem of
detection limit, presence of active cysteine cathepsins was
investigated by surface plasmon resonance with a BIAcore
1000 system. Biot-LVG-CHN2-treated BALF samples showed
a significantly increased signal (expressed as resonance units-
RU on streptavidin-coated dextran). This corresponds to a
stronger and specific interaction on the biosensor surface,
compared to E-64-treated samples used as unlabelled controls
(Fig. 3). The higher affinity of LVG-CHN2-treated BALF
samples to streptavidin is reinforced by a lower desorption
induced by NaOH 20 Al injection after the dissociation phase
compared to unlabelled controls. Overall, these results show
that cysteine cathepsins from patients with silicosis are still
enzymatically active in BALFs, as reported for patients
Fig. 2. Specific labeling of cysteine cathepsins by a cystatin-derived probe.
Titrated cathepsins B, H, K, L and S (1 AM) were incubated for 1 h at 37 -C in
the activity buffer with Biotinyl-Leu-Val-Gly-CHN2 (300-fold molar excess)
(), prior separation by a 12% (w/v) SDS-PAGE under reducing conditions
[23]. Following electroblotting onto a nitrocellulose sheet, enzymes were
incubated with an extravidin-peroxidase conjugate (diluted 1:500) for 2 h at
room temperature. The peroxidase activity was further revealed in the presence
of 4-chloro-1-naphthol (Renaissance 4 CN plus system). Control experiments
(+) were performed by pre-incubating cysteine cathepsins with unlabelled E-64
(10 AM) prior addition of Biotinyl-Leu-Val-Gly-CHN2 (300 AM).
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disorders [18] or cystic fibrosis [34].
3.2. Proteolytic activities of cysteine cathepsins in silicotic BAL
fluids
CP activities were then measured using differential substrate
specificity and stability at neutral pH, and selective inhibition
by small synthetic inhibitors to distinguish between individual
cathepsins (see the Materials and methods section). All
samples hydrolyzed Z-Phe-Arg-AMC, Z-Arg-Arg-AMC, Z-
Leu-Arg-AMC and H-Arg-AMC, confirming the presence of
active CPs in BAL fluids, as deduced from BIAcore analysis.
Individual concentrations of BALF cysteine cathepsins were
reported in Fig. 4 (the horizontal bars represent the calculated
median for each enzyme). No difference of concentrations was
observed in the three samples corresponding to silicotic
patients with a smoking history. Cathepsin H is the most
abundant among studied CPs (median value: 36.5 nM), while
cathepsins B (median value: 21.5 nM) and L (median value:
8 nM) are the most abundant thiol-dependent endoproteasesFig. 3. Specific detection by SPR of active cysteine cathepsins in BAL fluids.
(1) BAL fluids from silicotic patients were incubated in the assay buffer with
Biot-LVG-CHN2 (100 AM) for 4 h at 30 -C, as described in Materials and
methods, prior analysis by plasmon resonance according to the manufacturer
(BIAcore International). (2) The same experience was repeated by treatment of
BALF samples by the unlabelled CP-specific inhibitor E-64 (45 AM). One
representative BALF sample is shown for the sake of clarity.(35 nM). Conversely cathepsin S is poorly expressed (median
value: 0.8 nM). The overall concentration is approximately 10-
fold lower than the average concentration of active CPs
(962T347 nM; median: 885 nM) found in BALFs from
patients with acute lung infiltrative inflammatory disorders
[18]. Taken together that CPs are secreted by differentiated
macrophages, that cathepsin K is possible marker of inflam-
mation infiltrative inflammatory disorders [35–37], and that
silicosis is characterized by an important recruitment of
macrophages, the level of extracellular CPs in BAL fluids
may partly reflect the severity of the inflammation. In addition,
the enzymatic activity on Z-Phe-Arg-AMC was not increased
by incubating BAL fluids under acidic conditions (100 mM
Na-acetate buffer pH 4.0) at 37 -C for 0 to 5 h. This absence of
autocatalytic activation confirms western blot analysis, and
show that BAL fluids from patient with silicosis do not
represent a reservoir of activatable CPs, due to the lack of CP
precursors.
3.3. Inhibitory potential of silicotic BAL fluids
Specific circulating inhibitors of CPs have been reported in
numerous biological fluids, including epithelial lining fluids
(see, for review, [38]). In the present study, western blot
analysis indicated the presence of weak immunoreactive bands
corresponding to both degraded forms of high and/or low
molecular weight kininogens (including a major fragment of
¨32 kDa) and of cystatin C (¨13 kDa) (data not shown). The
residual CP inhibitory capacity (expressed as inhibitory site
equivalents) was evaluated by measuring the ability of BAL
fluids to inhibit E-64-titrated papain. A median CPI value of 9
nM was found, that indicates that the CP/CPI ratio (¨8-fold)
was unbalanced in favor of enzymes. Taken together that CPs
are potent elastolytic and/or collagenolytic enzymes infiltrative
inflammatory disorders [12,16], and the imbalance in the
expression of CPs and their specific inhibitors, it could be
assumed that cysteine cathepsins – in addition to the newly
described cathepsin V [21], neutrophile elastase and matrix
metalloproteases (MMP 2=gelatinase A, MMP 9=gelatinase
B, MMP 12=macrophage metalloelastase) [8] – may partic-Fig. 4. Individual active forms of cathepsins B, H, K, L and S and CP/CP
balance in silicotic bronchoalveolar fluids. The horizontal bars represent the
calculated median value. CPI: expressed as inhibitory site (cystatin-like) eq.I
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degradation of the major components of the extracellular
matrix (collagen, laminin, and gelatin) and its remodeling that
occur during progression of silicosis. Interestingly, a compa-
rable CP/CPI balance (3- to 5-fold) was found in favor of
cysteine cathepsins for patients suffering from acute lung
injuries, despite both CPs (962T347 nM) and CPIs (147T23
nM) exhibit higher concentrations [18]. This observation raises
the question of the upregulation/over expression of lung
cysteine cathepsins under acute inflammatory episodes vs.
chronic inflammations as reported for better documented
peptidases (reviewed by Owen and Campbell, [39]). Unfortu-
nately, as recently claimed by Bogyo and co-workers [40], the
understanding of the contribution of individual cathepsins in
the context of complex proteolytic events remains in its infancy
and has to be clarified.
In conclusion, we report for the first time the presence of
mature active forms of cathepsins B, H, K, L and S in human
inflammatory bronchoalveolar lavage fluids from patients with
silicosis. Conversely we failed to identify zymogens, suggest-
ing the lack of a pool of activatable cysteine cathepsins. Weak
amount of immunoreactive cystatin C was detected in BALF
supernatants, and kininogens are degraded. As a possible
result, the uncontrolled cathepsins could participate to the
pathophysiological breakdown/remodeling of the extracellular
matrix occurring during silicosis.
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